TY - JOUR
T1 - Improving Adjuvant Liver-Directed Treatment Recommendations for Unresectable Hepatocellular Carcinoma
T2 - An Artificial Intelligence-Based Decision-Making Tool
AU - Mo, Allen
AU - Velten, Christian
AU - Jiang, Julie M.
AU - Tang, Justin
AU - Ohri, Nitin
AU - Kalnicki, Shalom
AU - Mirhaji, Parsa
AU - Nemoto, Kei
AU - Aasman, Boudewijn
AU - Garg, Madhur
AU - Guha, Chandan
AU - Brodin, N. Patrik
AU - Kabarriti, Rafi
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2022
Y1 - 2022
N2 - PURPOSELiver-directed therapy after transarterial chemoembolization (TACE) can lead to improvement in survival for selected patients with unresectable hepatocellular carcinoma (HCC). However, there is uncertainty in the appropriate application and modality of therapy in current clinical practice guidelines. The aim of this study was to develop a proof-of-concept, machine learning (ML) model for treatment recommendation in patients previously treated with TACE and select patients who might benefit from additional treatment with combination stereotactic body radiotherapy (SBRT) or radiofrequency ablation (RFA).METHODSThis retrospective observational study was based on data from an urban, academic hospital system selecting for patients diagnosed with stage I-III HCC from January 1, 2008, to December 31, 2018, treated with TACE, followed by adjuvant RFA, SBRT, or no additional liver-directed modality. A feedforward, ML ensemble model provided a treatment recommendation on the basis of pairwise assessments evaluating each potential treatment option and estimated benefit in survival.RESULTSTwo hundred thirty-seven patients met inclusion criteria, of whom 54 (23%) and 49 (21%) received combination of TACE and SBRT or TACE and RFA, respectively. The ML model suggested a different consolidative modality in 32.7% of cases among patients who had previously received combination treatment. Patients treated in concordance with model recommendations had significant improvement in progression-free survival (hazard ratio 0.5; P =.007). The most important features for model prediction were cause of cirrhosis, stage of disease, and albumin-bilirubin grade (a measure of liver function).CONCLUSIONIn this proof-of-concept study, an ensemble ML model was able to provide treatment recommendations for HCC who had undergone prior TACE. Additional treatment in line with model recommendations was associated with significant improvement in progression-free survival, suggesting a potential benefit for ML-guided medical decision making.
AB - PURPOSELiver-directed therapy after transarterial chemoembolization (TACE) can lead to improvement in survival for selected patients with unresectable hepatocellular carcinoma (HCC). However, there is uncertainty in the appropriate application and modality of therapy in current clinical practice guidelines. The aim of this study was to develop a proof-of-concept, machine learning (ML) model for treatment recommendation in patients previously treated with TACE and select patients who might benefit from additional treatment with combination stereotactic body radiotherapy (SBRT) or radiofrequency ablation (RFA).METHODSThis retrospective observational study was based on data from an urban, academic hospital system selecting for patients diagnosed with stage I-III HCC from January 1, 2008, to December 31, 2018, treated with TACE, followed by adjuvant RFA, SBRT, or no additional liver-directed modality. A feedforward, ML ensemble model provided a treatment recommendation on the basis of pairwise assessments evaluating each potential treatment option and estimated benefit in survival.RESULTSTwo hundred thirty-seven patients met inclusion criteria, of whom 54 (23%) and 49 (21%) received combination of TACE and SBRT or TACE and RFA, respectively. The ML model suggested a different consolidative modality in 32.7% of cases among patients who had previously received combination treatment. Patients treated in concordance with model recommendations had significant improvement in progression-free survival (hazard ratio 0.5; P =.007). The most important features for model prediction were cause of cirrhosis, stage of disease, and albumin-bilirubin grade (a measure of liver function).CONCLUSIONIn this proof-of-concept study, an ensemble ML model was able to provide treatment recommendations for HCC who had undergone prior TACE. Additional treatment in line with model recommendations was associated with significant improvement in progression-free survival, suggesting a potential benefit for ML-guided medical decision making.
UR - http://www.scopus.com/inward/record.url?scp=85131480316&partnerID=8YFLogxK
U2 - 10.1200/CCI.22.00024
DO - 10.1200/CCI.22.00024
M3 - Article
C2 - 35671414
AN - SCOPUS:85131480316
SN - 2473-4276
VL - 6
JO - JCO Clinical Cancer Informatics
JF - JCO Clinical Cancer Informatics
M1 - e2200024
ER -